GIT1

Across TCGA pan-cancer cohorts, GIT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GIT1 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GIT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GIT1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where GIT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.291	0.779	.021	8	view →
CCRCC	DFS	Median	III,IV	0.818	0.244	.031	6	view →
PDAC	DFS	Median	All	0.837	0.688	.014	5	view →
LUAD	OS	Tertile	II,III,IV	0.320	0.839	.026	3	view →
HNSC	DFS	Tertile	All	0.465	0.701	.020	3	view →
UCEC	DFS	Quartile	All	0.836	0.956	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GIT1–LSCC (DFS)

Open the LSCC breakdown →